| |
HBV - Arbutus Announces Corporate Update
and First Quarter 2017 Financial Results
|
| |
| |
http://investor.arbutusbio.com/releasedetail.cfm?ReleaseID=1024897
3 HBV Product Candidates Progressing in Clinical Development
Cash Runway to Late 2018
Company to Host a Corporate Update Conference Call Today at 4:30 PM ET
VANCOUVER, British Columbia and WARMINSTER, Pa., May 04, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced its first quarter 2017 unaudited financial results and provided a corporate update.
"Arbutus continued to make significant advancements in its HBV pipeline in the first quarter of this year," said Dr. Mark J Murray, Arbutus' President and CEO. "As projected, three of our HBV candidates are now in clinical development. Our lead product has already generated significant reductions in serum HBsAg in Phase II, the results of which were presented at EASL last month. To further advance our pipeline, we are working hard to move additional small molecule programs into the clinic as early as next year. We believe Arbutus' pipeline will enable new treatment regimens to achieve greater HBV cure rates than the current standard of care."
Recent Highlights and Developments
⋅AB-423 (HBV capsid assembly inhibitor) began Phase I study in healthy volunteers 1Q17. This will enable progression to a multi-dosing study in HBV patients in 2H17.
⋅ARB-1467 Phase II Cohort 4 began bi-weekly dosing in HBeAg- patients in 1Q17 and enrollment is complete. Initial results from this cohort will be available in 3Q17.
⋅ARB-1740 ongoing Phase II multi-dosing study in HBV patients to enable a potency comparison between ARB-1467 and ARB-1740. Results will be available in 2H17.
⋅ARB-1467 Phase II Cohorts 1, 2 & 3 results were presented at the EASL Conference in April demonstrating step-wise, additive reduction in serum HBsAg that was consistent between HBeAg+ and HBeAg- patients.
⋅Acuitas' appeal of injunction decision was denied, thereby preventing Acuitas from sublicensing Arbutus' LNP technology.
⋅Daniel Burgess was appointed to Arbutus' Board of Directors and its Audit Committee.
Upcoming Milestones
⋅3Q17: Initial ARB-1467 Phase II Cohort 4 clinical study results.
⋅Mid-2017: Phase III results expected for Alnylam's Patisiran (Arbutus to receive royalties on sales).
⋅2H17: Initiate AB-423 Phase II MAD Study.
⋅2H17: ARB-1740 multi-dosing patient study results.
|
|
| |
| |
|
|
|
